Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Multimodal LLM for Breast Cancer Radiotherapy Target Auto-Contouring and Planning

11 novembre 2026 aggiornato da: Xiaohui Zhao

Multimodal Data Fusion-Based Artificial Intelligence Large Language Model for Automated Target Volume Contouring and Intelligent Treatment Planning in Breast Cancer Radiotherapy: A Multicenter Ambidirectional Cohort Study

Breast cancer remains the most prevalent malignancy among women worldwide, with a continuously increasing incidence. As a crucial component of comprehensive cancer treatment, radiotherapy plays a key role in reducing local recurrence rates and improving overall survival outcomes. However, traditional radiotherapy target volume contouring and treatment planning design rely heavily on clinician expertise, presenting challenges such as prolonged processing time, significant inter-observer variability, and high subjectivity in dose optimization. Although artificial intelligence has made substantial progress in automated contouring and planning, conventional single-modal models still face major limitations. These models struggle to effectively integrate clinical text, tumor biological characteristics, and dose distribution factors, resulting in restricted generalizability. Therefore, developing an intelligent radiotherapy assistance system capable of multimodal data fusion is of high clinical significance to enhance precision and efficiency in breast cancer radiotherapy.

This study aims to develop an innovative breast cancer radiotherapy assistance system based on a multimodal large language model. By integrating multimodal imaging data (including CT, MRI, and ultrasound), pathology reports, and structured electronic health record text, the system realizes end-to-end intelligence from target volume contouring to treatment plan generation. Employing a multicenter, ambidirectional cohort design, the study collects comprehensive clinical data from breast cancer patients who have undergone breast-conserving surgery or mastectomy. Technologically, the system innovatively combines the natural language processing capabilities of large language models with the image analysis strengths of deep learning, utilizing attention mechanisms to achieve deep fusion and interactive comprehension of heterogeneous medical data. Notably, the system breaks through traditional radiotherapy planning workflows by jointly optimizing target contouring and dose planning as a unified pipeline, applying reinforcement learning algorithms to dynamically balance target volume coverage with organ-at-risk protection. The outcomes of this study will provide an important paradigm for the clinical application of AI in radiation oncology and advance the field of precision radiotherapy.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Osservativo

Iscrizione (Stimato)

51000

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Guangdong
      • Guangzhou, Guangdong, Cina, 510120
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Contatto:
        • Investigatore principale:
          • Xiaohui Zhao, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population includes patients with breast cancer from multiple medical centers. The retrospective cohort comprises patients treated at Sun Yat-sen Memorial Hospital (n=35,000) and external collaborating centers (Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Zhoukou Central Hospital, and Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, n=15,000) between January 1, 2002, and October 31, 2025. The prospective test cohort comprises patients prospectively enrolled at Sun Yat-sen Memorial Hospital starting from January 1, 2026 (n=1,000).

Descrizione

Inclusion Criteria:

  • Patients with pathologically confirmed breast malignant tumors who require postoperative adjuvant radiotherapy following radical surgery.
  • Availability of complete pathology reports.
  • Availability of complete imaging examinations and reports (such as CT, MRI, ultrasound, X-ray).
  • Availability of standardized clinical medical records.

Exclusion Criteria:

  • Patients with missing data.
  • Patients with primary multiple cancers.
  • Patients receiving salvage or palliative radiotherapy.
  • Patients receiving accelerated partial breast irradiation (APBI).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: OTHER

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Retrospective Training and Internal Validation Cohort

Retrospective collection of clinical data, multimodal images (MRI, CT, ultrasound, X-ray), pathology reports, and radiotherapy plans from patients with breast cancer treated at Sun Yat-sen Memorial Hospital between January 1, 2002, and October 31, 2025. This cohort (n=35,000) is used for model training and internal validation of the multimodal LLM-assisted automated contouring and radiotherapy planning system.

The study evaluates an innovative multimodal large language model (LLM) system designed for automated target volume delineation and intelligent treatment planning in post-operative breast cancer radiotherapy. The system integrates clinical text, multimodal imaging (CT, MRI, ultrasound, X-ray), and pathology data to joint-optimize contouring and dose planning without direct patient intervention.

Retrospective External Validation Cohort

Retrospective collection of data from external collaborative centers (Sun Yat-sen Memorial Hospital Shenzhen Hospital, Zhoukou Central Hospital, and Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) between January 1, 2002, and October 31, 2025 (total n=15,000). This cohort is used to evaluate the external generalizability and robustness of the multimodal AI model.

The study evaluates an innovative multimodal large language model (LLM) system designed for automated target volume delineation and intelligent treatment planning in post-operative breast cancer radiotherapy. The system integrates clinical text, multimodal imaging (CT, MRI, ultrasound, X-ray), and pathology data to joint-optimize contouring and dose planning without direct patient intervention.

Prospective Test Cohort

Prospective collection of data from patients with breast cancer treated at Sun Yat-sen Memorial Hospital starting from January 1, 2026 (n=1,000). This cohort undergoes double-blind evaluation to prospectively test the performance of the multimodal LLM-driven target volume auto-segmentation and intelligent radiotherapy planning system in clinical practice.

The study evaluates an innovative multimodal large language model (LLM) system designed for automated target volume delineation and intelligent treatment planning in post-operative breast cancer radiotherapy. The system integrates clinical text, multimodal imaging (CT, MRI, ultrasound, X-ray), and pathology data to joint-optimize contouring and dose planning without direct patient intervention.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Dice Similarity Coefficient (DSC) of Target Volume Auto-Segmentation
Lasso di tempo: Baseline

Evaluation of the Dice Similarity Coefficient (DSC) between AI-generated automatic breast cancer target volume contours and expert manual contours.

Baseline

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
95% Hausdorff Distance (95HD) of Target Volume Auto-Segmentation
Lasso di tempo: Baseline

Evaluation of the 95% Hausdorff Distance (95HD) between AI-generated automatic breast cancer target volume contours and expert manual contours.

Baseline
Intersection over Union (IoU) of Target Volume Auto-Segmentation
Lasso di tempo: Baseline

Evaluation of the Intersection over Union (IoU) between AI-generated automatic breast cancer target volume contours and expert manual contours.

Baseline
Clinical Evaluation Score of Target Volume Auto-Segmentation
Lasso di tempo: Baseline

Blinded evaluation by radiation oncology experts using the Investigator-Developed Cancer Target Volume Contouring Performance Evaluation Scale, a structured 5-point clinical evaluation scale. The scale assesses five dimensions: laterality accuracy (0 to 1 point), radiotherapy type suitability (0 to 1 point), target volume definition (0 to 1.5 points), coverage (0 to 1 point), and structural integrity (0 to 0.5 points). The total score ranges from a minimum of 0 to a maximum of 5, where higher scores indicate better target volume contouring quality and clinical acceptability.

Baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Xiaohui Zhao, MD, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

9 novembre 2026

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

31 dicembre 2027

Date di iscrizione allo studio

Primo inviato

2 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • SYSKY-2026-014-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .